be achieved. Total discounted costs in 23.5 years were 557 766.80 PLN (1EUROϭ3.96 PLN) for patients subjected to 200 days prophylaxis and 542 509.92 PLN for patients subjected to 110 days prophylaxis. The incremental cost-effectiveness ratio (ICER) was 39,669 PLN and cost-utility ratio (ICUR) 48,008 PLN. Sensitivity analysis confirmed the base case analysis results. The results were sensitive only to the time horizon assumed (when time horizon was shorter than 4 years ICER/ICUR were above the accepted 110,000 PLN cost-effectiveness threshold). CONCLUSIONS: The prolongation of CMV disease prophylaxis in kidney transplant recipients from 110 to 200 days is highly cost-effective from Polish payer perspective. Medicine and Surgery, Milano, Milano, Italy, 3 A. Manzoni Hospital, Lecco, Lecco, Lecco, Italy, 4 "L. Sacco" Hospital Authority, Milano, Milano, Italy OBJECTIVES: This study will evaluate lifetime cost-utility of a therapy based on lopinavir/ritonavir vs atazanavir ϩ ritonavir, using a tenofovir-emtricitabine backbone, in an Italian cohort of HIV infected anti-retroviral-naïve patients. An international literature review revealed, that there are limited useful data to inform Italian decision makers, taking into consideration Country specific costs and utility. METHODS: Starting from the Broder (2011) Markov microsimulation model and CASTLE study data, an Italian model was developed to specify direct costs and health outcomes from Italian HIV-infected patients and their treatment, adopting a national health service (NHS) payer perspective. The Health State (HS) transition probabilities were assessed within a sample of 319 patients on treatment within the Lombardy Region (the probability vector took into consideration the results of the 96-week CASTLE trial, the principal published literature and the evidence related to the Italian population in terms of cholesterol changes, coronary heart disease (CHD) events and adverse events (AEs). Costs related to AEs and to the care of HIVϩ patients were correlated to clinical effectiveness data, as well as institutional indications, protocols and reimbursement tariff of hospitals located in Lombardy Region. RESULTS: The newly developed Italian Markov model consisting of 8 HS, informs about the distribution of the Italian population, and forecasting the evolution of the clinical pathway of anti-retroviral-naïve patients through different stages up to death. Clinical effectiveness and absorption of resources were investigated to truly represent the Italian HIV context. CONCLUSIONS: The innovative method of this Markov model construction based on national data, ensures the opportunity of a closer results alignment to specific Italian costs, and to its usability from an Italian decision making and payer's perspective. OBJECTIVES: Every year 5-25% of the world's population suffers from influenza. Influenza and ILI (influenza like illness) among working adults are responsible for the enhanced sickness absenteeism, limited work capacity and efficiency, as well as for the increased health service demand. The aim of this pilot study was to estimate the indirect cost of influenza and ILI (both absenteeism and presenteeism) from emloper's perspective. METHODS: Data was collected from Polish citizens in working age, who were employed at the time of collecting data. Human Capital Approach method was used in quantifying costs. Modified version of Work Productivity and Activity Impairment General Health questionnaire was used to estimate absenteeism and presenteeism in the population. Responders were questioned about the period from the first day of January 2011 to the day of the questionnaire completion, which represents the period when the highest ILI incidence rate. The results of the questionnaire were extrapolated for the whole year of 2011. The indirect costs were calculated on the basis of the average gross wage value in the corporate sector in 2011, which amounts to 911 EUR (1 EURϭ3.95 PLN). RESULTS: The final population comprised 134 employees (average age 31 years, 56.7% men). Immunized against influenza were 23.1% of the people who participated in the study. 53.7% of all respondents reported that during the investigation period had influenza or influenza-like symptoms. The productivity loss at workplace due to illness was estimated at 4.0% (3,2 vs. 4,2, Immunized vs. non-immunized, respectivetly; pϭ0,44). Estimated absenteeism equaled 2.2% (1,7 vs 2,4, Immunized vs non-immunized, respectively; pϭ0,88). CONCLUSIONS: Indirect costs of productivity loss due to influenza and ILI are substantial to Polish economy. Due to the relatively small non-representative population results should be treated with caution. 
OBJECTIVES: Every year 5-25% of the world's population suffers from influenza. Influenza and ILI (influenza like illness) among working adults are responsible for the enhanced sickness absenteeism, limited work capacity and efficiency, as well as for the increased health service demand. The aim of this pilot study was to estimate the indirect cost of influenza and ILI (both absenteeism and presenteeism) from emloper's perspective. METHODS: Data was collected from Polish citizens in working age, who were employed at the time of collecting data. Human Capital Approach method was used in quantifying costs. Modified version of Work Productivity and Activity Impairment General Health questionnaire was used to estimate absenteeism and presenteeism in the population. Responders were questioned about the period from the first day of January 2011 to the day of the questionnaire completion, which represents the period when the highest ILI incidence rate. The results of the questionnaire were extrapolated for the whole year of 2011. The indirect costs were calculated on the basis of the average gross wage value in the corporate sector in 2011, which amounts to 911 EUR (1 EURϭ3.95 PLN). RESULTS: The final population comprised 134 employees (average age 31 years, 56.7% men). Immunized against influenza were 23.1% of the people who participated in the study. 53.7% of all respondents reported that during the investigation period had influenza or influenza-like symptoms. The productivity loss at workplace due to illness was estimated at 4.0% (3,2 vs. 4,2, Immunized vs. non-immunized, respectivetly; pϭ0,44). Estimated absenteeism equaled 2.2% (1,7 vs 2,4, Immunized vs non-immunized, respectively; pϭ0,88). CONCLUSIONS: Indirect costs of productivity loss due to influenza and ILI are substantial to Polish economy. Due to the relatively small non-representative population results should be treated with caution. 
Infection

OBJECTIVES:
To assess adherence to treatment for HCV monoinfected and HCV/ HIV co-infected patients, interim analysis at 12 weeks after therapy initiation. METHODS: Observational, prospective study performed by 120 investigators in Spain. Patients were hepatitis C (HCV) monoinfected or HCV/HIV co-infected, Ն18 years and naïve to HCV treatment. Visits were at treatment initiation (baseline), 4, 12, and every 24 weeks during HCV therapy and 24 weeks after finalization; only interim results up to wk12 are presented. Each visit assessed adherence by Adhepta and Morinsky-Green questionnaires. Adhepta questionnaire includes two questions related to treatment adherence and 11 (monoinfected) or 13 (co-infected) questions about reasons for non-adherence; non-adherence to treatment was assessed following the 80/80/80 rule (not administered any HCV drug on Ն20% of the occasions). RESULTS: Evaluable patients were 1,120, 801 monoinfected (68.3% male) and 319 co-infected (74.9% male). Mean (SD) age was 45.3 (8.8) years. Nonadherent patients by Adhepta were 2.5% and 3.5% for monoinfected at wk4 and wk12, respectively; and 2.7% and 2.5% patients, among co-infected. No differences between study groups were observed. Non-adherent patients by Morisky-Green were 14.0% and 14.8% at wk4, and wk12, respectively for monoinfected; and 23.3% and 23.2% for co-infected. Monoinfected patients were more adherent to treatment than co-infected patients at wk4 and wk12 (pϽ0.05). Assessed by Adhepta questionnaire, non-adherence most common reason reported was 'forgetting to take the drug' (8.2% monoinfected and 10.8% co-infected). CONCLUSIONS: Adherence to treatment remains constant through 12 weeks after treatment initiation. Differences in treatment adherence observed between both questionnaires must be compared at the end of the HCV treatment and analysing their correlation with patient self-reported medication record. 
PIN87 HEPATITIS C TREATMENT CONTINUATION RATES IN TREATMENT-NAÏVE GENOTYPE 1 PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
OBJECTIVES:
Determine real-life treatment continuation rates of chronic Hepatitis C (HCV) treatment from a database of medicine dispensation in the Brazilian public healthcare system. METHODS: Monthly data from a public database of medicine dispensation was analyzed for a period of 17 months. The patient cohort was defined as all new HCV (CID10 B18.2) patients initiating treatment between January and December 2009. To identify HCV genotype 1 (G1) patients, it was assumed G1 patients initiated treatment with the pegylated forms of the interferons (pegIFN), as defined by the Brazillian national guidelines for HCV. RESULTS: Between January and December 2009, 10,992 patients began treatment for HCV. Around 58% of these patients were male with a median age of 49.7 years. Of these, 82% of patients (9,019) were considered G1 as they began treatment with pegIFN and/or ribavirin. Almost all patients (97%) began treatment with the treatment combination pegIFN and ribavirin, with an equal split among both brands of pegIFN. For all HCV patients treatment mean/median was 38,3/40 weeks compared to 40.2/44.0 weeks for G1 patients. At week 48, 63% of all HCV patients had discontinued treatment compared to 58% of G1 patients. At week 24, around 19% of all HCV patients had discontinued treatment compared to 18% of G1 patients. The maximum observed treatment duration was 85 weeks in both all HCV and G1 patients. CONCLUSIONS: Discontinuation rates before week 24 were similar between all HCV and G1 patients. Although 48 weeks of treatment is the established duration for G1 patients, the majority of patients discontinue treatment earlier. These data, however, do not guarantee patients actually receive treatment, as it follows medicine dispensation. 
PIN88 LATE IMMUNIZATION DOSES RECEIVED BY CHILDREN YOUNGER THAN TWO YEARS
OBJECTIVES:
Immunization dose was considered as a late immunization dose if it was administered after the recommended age. The aims of this study are to determine the frequency and percent of this type of doses among child immunization schedule, and to determine the number of late immunization dose received by each child. METHODS: Data was collected retrospectively from 528 children immunization cards in Iraq to obtain the immunization history of each individual child. This study was restricted the analyses to the vaccines administered before age 2 years. Each children must received seven doses at seven times, every dose consist of many types of vaccines. RESULTS: More than 63% of late immunization doses were shown in the third dose (OPVϩDTP) at fourth month of child life. Hundred and forty five children were immunized with four late immunization doses out of seven immunization doses, and 1.5% of children were immunized with 7 late immunization doses. CONCLUSIONS: This study found that compliance with WHO immunization recommendations is low and inappropriate immunization doses were occur frequently, and leading to incomplete or partial immunization compliance. With an increase in parent's knowledge of immunization guidelines against infectious agents, it is very important to implement strategies that will lead to improved and developed immunization practice and childhood immunization coverage in the future.
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